Price
$0.5
Decreased by -5.32%
Dollar Volume
36.23 K
ADR%
12.79
Earnings Report Date (estimate)
Jan 25, 23 (N/A)
Market Cap.
37.22 M
Shares Float
35.67 M
Shares Outstanding
74.45 M
Beta
1.44
Price / Earnings
-1.23
BPR
4.21
20D Range
0.38 0.55
50D Range
0.38 0.62
200D Range
0.38 1.61
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Mar 31, 20 -0.39
Increased by +26.42%
-0.14
Decreased by -178.57%
Nov 4, 19 -0.14
Decreased by -55.56%
-0.12
Decreased by -16.67%
Aug 29, 19 -0.25
Increased by +75.00%
-0.13
Decreased by -92.31%
May 29, 19 -0.15
Increased by +85.00%
-0.05
Decreased by -200.00%
Sep 27, 18 -0.53
Decreased by -5.92 K%
-0.44
Decreased by -20.45%
Aug 16, 18 -0.09
Increased by +91.00%
-0.47
Increased by +80.85%
Mar 21, 18 -1.00
Increased by 0.00%
-0.66
Decreased by -51.52%
Nov 13, 17 -1.00
Decreased by -277.68 K%
-0.65
Decreased by -53.85%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 22 0.00
Decreased by N/A%
-5.68 M
Decreased by -30.68%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-5.18 M
Increased by +11.34%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-5.79 M
Increased by +15.15%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-1.45 M
Decreased by -200.65%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-4.35 M
Increased by +47.74%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-5.84 M
Decreased by -72.48%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-6.82 M
Increased by +13.41%
Decreased by N/A%
Decreased by N/A%
Sep 30, 20 0.00
Decreased by N/A%
1.44 M
Increased by +156.21%
Increased by +N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.